# Stage B issuer identity follow-up — 2026-10-14

This is a follow-up to the [2026-10-13 Stage B checkpoint](box-range-stage-b-2026-10-13.md); it does not replace or rewrite that historical report. The frozen 48-task selection, RI v1 database and human annotations were not changed.

The previous aggregate reported 46/48 `names_compatible` rows. That field summarizes evidence across all dates, so it is too broad to treat both flagged names as conflicts known at the frozen decision date T. The revised read-only audit counts issuer evidence available by each task's T separately from later evidence. It uses RI v1's recorded construction database and verifies its SHA-256 before querying.

| Identity check | Actual result |
| --- | ---: |
| Distinct selected security IDs | 48 |
| One CIK with evidence available by T | 48/48 |
| Distinct CIKs in selected batch | 48 |
| CIK overlap with old pilot / Stage A / six references | 0 / 0 / 0 |
| All-time name-compatible rows | 46/48 |
| Incompatible name evidence available by T | 1/48 |
| Incompatible name evidence only after T | 1/48 |
| `official_identity` rows | 0/48 |

The one pre-T conflict has a plausible documented issuer-renaming explanation, but the research database still marks the identity observational. External corroboration does not silently promote `OBS` to `official_identity`, and the remaining provenance review is not complete. No symbol, date, security ID or private name mapping is published here. The executable query and aggregate [receipt](../evidence/box-range-stage-b-identity-followup-2026-10-14.json) allow rechecking the time boundary.

**Gate: PROVISIONAL.** This refinement removes one false historical concern caused by post-T information. It does not establish the independent issuer-level quality gate or detector accuracy. The separate human annotation store still has zero genuine revisions; no assistant labels, future outcomes or Stage C work were produced. The owner can continue blind structure labeling in the existing local page. Stage B exit still requires genuine human labels and the remaining issuer provenance review.
